Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Change in Cash: 2019-2025

Historic Change in Cash for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $4.5 million.

  • Fulcrum Therapeutics' Change in Cash rose 131.84% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.6 million, marking a year-over-year decrease of 159.90%. This contributed to the annual value of $32.8 million for FY2024, which is 443.56% up from last year.
  • Fulcrum Therapeutics' Change in Cash amounted to $4.5 million in Q3 2025, which was up 983.57% from $414,000 recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Change in Cash registered a high of $50.8 million during Q3 2022, and its lowest value of -$55.8 million during Q4 2022.
  • For the 3-year period, Fulcrum Therapeutics' Change in Cash averaged around $1.1 million, with its median value being -$768,000 (2023).
  • Examining YoY changes over the last 5 years, Fulcrum Therapeutics' Change in Cash showed a top increase of 6,189.58% in 2024 and a maximum decrease of 262.51% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Change in Cash (Quarterly) stood at -$30.1 million in 2021, then plummeted by 85.76% to -$55.8 million in 2022, then soared by 91.91% to -$4.5 million in 2023, then tumbled by 219.19% to -$14.4 million in 2024, then soared by 131.84% to $4.5 million in 2025.
  • Its Change in Cash stands at $4.5 million for Q3 2025, versus $414,000 for Q2 2025 and -$16.0 million for Q1 2025.